MEDSENIC receives a notice of allowance in the United States for a new patent that extends the use of arsenic trioxide to the treatment of relapsing forms of multiple sclerosis.
Strasbourg, France, September 29, 2021 - Medsenic, a clinical-stage biopharmaceutical company specializing in
the discovery and development of new indications and formulations of arsenic salts for the treatment of
severe autoimmune diseases, announced today that it has received from the US Patent and Trademark Office, a
notice of allowance for a patent that enhances the protection of Arscimed, its intravenous formulation
of arsenic trioxide, in the United States, particularly in the treatment of multiple sclerosis